To determine whether the improvements observed with ACA + anti-PD-1 extended to targeted therapies approved for use in metastatic RCC, we combined ACA with the mTOR inhibitor rapamycin or vehicle control (VC) administered in the drinking water (Figure 6A). This evidence concerns the gene PDCD1 and renal cell carcinoma.